Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials - PubMed (original) (raw)

Review

Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials

Maria Jose Sáez-Lara et al. Int J Mol Sci. 2016.

Abstract

The use of probiotics and synbiotics in the prevention and treatment of different disorders has dramatically increased over the last decade. Both probiotics and synbiotics are well known ingredients of functional foods and nutraceuticals and may provide beneficial health effects because they can influence the intestinal microbial ecology and immunity. The present study reviews the effects of probiotics and synbiotics on obesity, insulin resistance syndrome (IRS), type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD) in human randomized clinical trials. Select probiotics and synbiotics provided beneficial effects in patients with obesity, mainly affecting the body mass index and fat mass. Some probiotics had beneficial effects on IRS, decreasing the cell adhesion molecule-1 levels, and the synbiotics decreased the insulin resistance and plasma lipid levels. Moreover, select probiotics improved the carbohydrate metabolism, fasting blood glucose, insulin sensitivity and antioxidant status and also reduced metabolic stress in subjects with T2D. Some probiotics and synbiotics improved the liver and metabolic parameters in patients with NAFLD. The oral intake of probiotics and synbiotics as co-adjuvants for the prevention and treatment of obesity, IRS, T2D and NAFLD is partially supported by the data shown in the present review. However, further studies are required to understand the precise mechanism of how probiotics and synbiotics affect these metabolic disorders.

Keywords: insulin resistance; metabolic syndrome X; non-alcoholic fatty liver disease; obesity; probiotics; randomized clinical trial; synbiotics; type 2 diabetes.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Backhed F., Ley R.E., Sonnenburg J.L., Peterson D.A., Gordon J.I. Host bacterial mutualism in the human intestine. Science. 2005;307:1915–1920. doi: 10.1126/science.1104816. - DOI - PubMed
    1. Hooper L.V., Midtvedt T., Gordon J.I. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu. Rev. Nutr. 2002;22:283–307. doi: 10.1146/annurev.nutr.22.011602.092259. - DOI - PubMed
    1. Plaza-Díaz J., Fernandez-Caballero J.Á., Chueca N., Garcia F., Gómez-Llorente C., Sáez-Lara M.J., Fontana L., Gil A. Pyrosequencing analysis reveals changes in intestinal microbiota of healthy adults who received a daily dose of immunomodulatory probiotic strains. Nutrients. 2015;7:3999–4015. doi: 10.3390/nu7063999. - DOI - PMC - PubMed
    1. McCoy K.D., Köller Y. New developments providing mechanistic insight into the impact of the microbiota on allergic disease. Clin. Immunol. 2015;159:170–176. doi: 10.1016/j.clim.2015.05.007. - DOI - PMC - PubMed
    1. Bass R., Eneli I. Severe childhood obesity: An under-recognised and growing health problem. Postgrad. Med. J. 2015;91:639–645. doi: 10.1136/postgradmedj-2014-133033. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources